Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Derami…

Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control ...
TipRanks on MSN

Capricor Therapeutics announces publication in Biomedicines on Deramiocel

Capricor Therapeutics (CAPR) announced the publication in Biomedicines, an international peer-reviewed journal, describing a novel in-vitro ...
Fierce Biotech

uniQure's ballyhooed gene therapy for Huntington's hits FDA roadblock

The FDA is said to be making a U-turn on uniQure’s one-time gene therapy candidate for Huntington’s disease despite the treatment being hailed as a game-changer. | FDA is said to be making a U-turn on ...

Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10

Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ETSAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Capricor ...

Capricor Therapeutics Faces Legal Challenge as Key Drug Trial Nears Completion

Capricor Therapeutics finds itself navigating turbulent waters as a federal securities class action lawsuit casts uncertainty over the company's future. The legal investigation, made public on October ...